Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies Treatment (PDQ®)–Health Professional Version

Go to Patient Version

Changes to This Summary (11/13/2018)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

Classification of Pediatric Myeloid Malignancies

Added text about the presentation, incidence, and outcome of patients with acute myeloid leukemia (AML) and t(16;21)(q24;q22) (RUNX1-CBFA2T3 AML) (cited Noort et al. as reference 72).

Added text about the presentation, incidence, and outcome of patients with AML and t(16;21)(p11;q22) (FUS-ERG AML).

Chronic Myelogenous Leukemia (CML)

Revised text about a phase II trial of dasatinib that included 84 children with newly diagnosed CML in chronic phase.

Revised text to state that depending on the patient’s mutation status, alternative kinase inhibitors such as dasatinib or nilotinib can be considered on the basis of the adult and pediatric experience with these agents.

Revised text about the U.S. Food and Drug Administration indications for the use of nilotinib in treating children with CML, including the results of two sponsored trials.

Added text to state that in 14 children with resistant or intolerant CML, 76% of patients were in complete cytogenetic remission, and 41% of patients had a major molecular response after 12 months of dasatinib therapy. Progression-free survival was 78% at 48 months.

Added text to state that in 44 children with CML who were resistant or intolerant to imatinib or dasatinib, 40.7% of patients achieved a major molecular response after 12 months of nilotinib therapy. After a median of 11.3 months, no patients had experienced disease progression.

This summary is written and maintained by the PDQ Pediatric Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.

< Previous section
Survivorship and Adverse Late Sequelae

Next section >
About This PDQ Summary